Clinical trial · Interventional
Patient-Centered Communication of Life Expectancy Estimates in Genitourinary Malignancies
A Patient-Centered Approach to Integration of Life Expectancy Into Treatment Decision Making for Patients With Genitourinary Malignancy
NCT03522155CI-TRIAL-00043227unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigators will conduct a randomized trial to determine if providing patient-specific life expectancy estimates during treatment counseling via a targeted, patient-centered communication approach improves shared decision making and reduces rates of overtreatment of genitourinary malignancies.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer Stage II | Malignant Bladder Neoplasm | CURATED_BROADER | 0.78 |
| Kidney Cancer Stage I | Malignant Kidney Neoplasm | CURATED_BROADER | 0.78 |
| Prostate Cancer Stage I | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
| Prostate Cancer Stage II | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patient-centered communication of life expectancy | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention Arm
- description
- Intervention: (1) Subjects will be provided with patient-specific LE estimates, (2) counseling physicians will receive "talking points" to assist in meaningful communication of life expectancy, and (3) subjects will complete a computer-based conjoint analysis exercise prior to counseling.
- interventionNames
- Behavioral: Patient-centered communication of life expectancy
- type
- NO_INTERVENTION
- label
- Standard-of-care Arm
- description
- Patients in the standard-of-care arm will not receive an intervention and will receive the usual standard of care for treatment counseling.
Primary outcomes (1)
- measure
- Decisional Conflict
- timeFrame
- At time of treatment decision, up to 12 weeks after diagnosis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed clinical T1-2 prostate adenocarcinoma with Gleason scores of 7 or less * Newly diagnosed clinical T1a kidney cancer or renal masses \< 4cm * Newly diagnosed clinical T2 nonmetastatic urothelial carcinoma of the bladder Exclusion Criteria: * Under 18 years of age * Subjects with difficulty communicating or dementia * Non-English speakers
References
Publications (5)
- BACKGROUNDDaskivich TJ, Tan HJ, Litwin MS, Hu JC. Life Expectancy and Variation in Treatment for Early Stage Kidney Cancer. J Urol. 2016 Sep;196(3):672-7. doi: 10.1016/j.juro.2016.03.133. Epub 2016 Mar 21. PMID 27012644
- BACKGROUNDDaskivich TJ, Lai J, Dick AW, Setodji CM, Hanley JM, Litwin MS, Saigal C; Urologic Diseases in America Project. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer. Cancer. 2014 Dec 1;120(23):3642-50. doi: 10.1002/cncr.28926. Epub 2014 Jul 17. PMID 25042117
- BACKGROUNDCho H, Klabunde CN, Yabroff KR, Wang Z, Meekins A, Lansdorp-Vogelaar I, Mariotto AB. Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. Ann Intern Med. 2013 Nov 19;159(10):667-76. doi: 10.7326/0003-4819-159-10-201311190-00005. PMID 24247672
- BACKGROUNDRyan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000 Jun 3;320(7248):1530-3. doi: 10.1136/bmj.320.7248.1530. No abstract available. PMID 10834905
- BACKGROUNDO'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995 Jan-Mar;15(1):25-30. doi: 10.1177/0272989X9501500105. PMID 7898294